Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To assess the long-term safety and efficacy of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome (CAPS).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Exp. Rheumatol.

Title: Clinical and experimental rheumatology

ISSN: 0392-856X

ISSN (Print): 0392-856X

Publication date (Electronic): December 16 2016

Volume: 35 Suppl 108

Issue: 6

Affiliations

[1 ] Laboratory of Paediatric Research, Medical Research Institute of Tokyo Medical School, Japan. yokotashumpei@gmail.com.

[2 ] Laboratory of Paediatric Research, Medical Research Institute of Tokyo Medical School, Japan.

[3 ] Department of Paediatrics, Kyoto University, Kyoto, Japan.

[4 ] Department of Paediatrics, Kyushu University, Fukuoka, Japan.

[5 ] Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.

[6 ] Novartis Pharma AG, Basel, Switzerland.

[7 ] Fukuoka Children's Hospital, Fukuoka, Japan.

Article

Publisher Item ID: 10184

PubMed ID: 27974104

SO-VID: ff310b8e-218d-4185-abe4-77076b636956

History

Data availability:

Comments

Comment on this article

Cited by 4

See all cited by